Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Use of a shuttle box model to assess the behavioral and analgesic effects of opioid injections in goldfish (Carassius auratus)

Influence Of Clonidine And Ketamine On M-Rna Expression In A Model Of Opioid-Induced Hyperalgesia In Mice

The development of behavioral sensitization induced by a single morphine exposure in adult zebrafish (Danio rerio)

Influence of chronic administration of morphine and its withdrawal on the behaviour of zebrafish

Development of an opioid self-administration assay to study drug seeking in zebrafish

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

The development of behavioral sensitization induced by a single morphine exposure in adult zebrafish (<i>Danio rerio</i>)

Nociceptive-like behavior and analgesia in silver catfish (Rhamdia quelen)

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Role of mu opioid receptor (MOR) agonist efficacy as a determinant of opioid antinociception in a novel assay of pain-depressed behavior in female and male mice

Assessment of orofacial nociceptive behaviors of mice with the sheltering tube method: Oxaliplatin-induced mechanical and cold allodynia in orofacial regions

Behavioral video coding analysis of chronic morphine administration in rats

Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice

Comparison of electroencephalographic changes in response to acute electrical and thermal stimuli with the tail flick and hot plate test in rats administered with opiorphin

Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.

[The Influence of GABAA Receptor on the Analgesic Action of Intrathecally Injected Oxysophoridine].

Morphine-Induced Antinociception and Fecal Motility in Rats Eating a High Fat/High Carbohydrate or Ketogenic Diet

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Effects of Pre-Training Morphine on Spatial Memory Acquisition and Retrieval in Mice

Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement

Evaluation of Side Effects Through Selective Ablation of the Mu Opioid Receptor Expressing Descending Nociceptive Facilitatory Neurons in the Rostral Ventromedial Medulla with Dermorphin-Saporin.